Essential Role of NK Cells in IgG Therapy for Experimental Autoimmune Encephalomyelitis

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Chong, Wai Po ^a,b   Ling, Man To ^a   Liu, Yinping ^a   Caspi, Rachel R ^b   Wong, Wai Man ^a   Wu, Wutian ^a   Tu, Wenwei ^a   Lau, Yu Lung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEMYELINATION; DRUG RECEPTOR BINDING; DRUG TARGETING; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; RISK REDUCTION;

ADOPTIVE TRANSFER; AMINO ACID SEQUENCE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DEMYELINATING DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; MICE; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA1;

MUS;

EID: 84875931257     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060862     Document Type: Article

References (40)

1. Nimmerjahn F, Ravetch JV, (2008) Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26: 513-533.
2. Achiron A, Margalit R, Hershkoviz R, Markovits D, Reshef T, et al. (1994) Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. J Clin Invest 93: 600-605.
3. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV, (2003) Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18: 573-581.
4. Inoue Y, Kaifu T, Sugahara-Tobinai A, Nakamura A, Miyazaki J, et al. (2007) Activating Fc gamma receptors participate in the development of autoimmune diabetes in NOD mice. J Immunol 179: 764-774.
5. Siragam V, Crow AR, Brinc D, Song S, Freedman J, et al. (2006) Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 12: 688-692.
6. Araujo LM, Chauvineau A, Zhu R, Diem S, Bourgeois EA, et al. (2011) Cutting edge: intravenous Ig inhibits invariant NKT cell-mediated allergic airway inflammation through FcgammaRIIIA-dependent mechanisms. J Immunol 186: 3289-3293.
7. Aubin E, Lemieux R, Bazin R, (2010) Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood 115: 1727-1734.
8. Moretta L, Ferlazzo G, Bottino C, Vitale M, Pende D, et al. (2006) Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 214: 219-228.
9. Hanna J, Gonen-Gross T, Fitchett J, Rowe T, Daniels M, et al. (2004) Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest 114: 1612-1623.
10. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, et al. (2004) Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 5: 1260-1265.
11. Bergmann C, Wild CA, Narwan M, Lotfi R, Lang S, et al. (2011) Human tumor-induced and naturally occurring Treg cells differentially affect NK cells activated by either IL-2 or target cells. Eur J Immunol 41: 3564-3573.
12. Bao Y, Han Y, Chen Z, Xu S, Cao X, (2011) IFN-alpha-producing PDCA-1+ Siglec-H- B cells mediate innate immune defense by activating NK cells. Eur J Immunol 41: 657-668.
13. Bryceson YT, March ME, Ljunggren HG, Long EO, (2006) Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 214: 73-91.
14. Jorgensen SH, Jensen PE, Laursen H, Sorensen PS, (2005) Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically. Neurol Res 27: 591-597.
15. Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, et al. (2008) Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111: 715-722.
16. Bettelli E, Sullivan B, Szabo SJ, Sobel RA, Glimcher LH, et al. (2004) Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med 200: 79-87.
17. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, et al. (2006) IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 177: 566-573.
18. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM, (2008) IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 205: 1535-1541.
19. Setoguchi R, Hori S, Takahashi T, Sakaguchi S, (2005) Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201: 723-735.
20. Horwitz DA, Zheng SG, Gray JD, (2003) The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets. J Leukoc Biol 74: 471-478.
21. Cooper MA, Fehniger TA, Caligiuri MA, (2001) The biology of human natural killer-cell subsets. Trends Immunol 22: 633-640.
22. Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, et al. (2004) Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol 173: 3716-3724.
23. Griseri T, Asquith M, Thompson C, Powrie F, (2010) OX40 is required for regulatory T cell-mediated control of colitis. J Exp Med 207: 699-709.
24. Brillard E, Pallandre JR, Chalmers D, Ryffel B, Radlovic A, et al. (2007) Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes. Exp Hematol 35: 416-425.
25. Tha-In T, Metselaar HJ, Tilanus HW, Groothuismink ZM, Kuipers EJ, et al. (2007) Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood 110: 3253-3262.
26. Jacobi C, Claus M, Wildemann B, Wingert S, Korporal M, et al. (2009) Exposure of NK cells to intravenous immunoglobulin induces IFN gamma release and degranulation but inhibits their cytotoxic activity. Clin Immunol 133: 393-401.
27. Bohn AB, Nederby L, Harbo T, Skovbo A, Vorup-Jensen T, et al. (2011) The effect of IgG levels on the number of natural killer cells and their Fc receptors in chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 18: 919-924.
28. Luger D, Silver PB, Tang J, Cua D, Chen Z, et al. (2008) Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 205: 799-810.
29. Moretta A, (2002) Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2: 957-964.
30. Hao J, Liu R, Piao W, Zhou Q, Vollmer TL, et al. (2010) Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med 207: 1907-1921.
31. Xu W, Fazekas G, Hara H, Tabira T, (2005) Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis. J Neuroimmunol 163: 24-30.
32. Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T, (1997) Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 186: 1677-1687.
33. Winkler-Pickett R, Young HA, Cherry JM, Diehl J, Wine J, et al. (2008) In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: alteration of primary adaptive responses. J Immunol 180: 4495-4506.
34. Kessel A, Ammuri H, Peri R, Pavlotzky ER, Blank M, et al. (2007) Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 179: 5571-5575.
35. Shi FD, Ljunggren HG, La Cava A, Van Kaer L, (2011) Organ-specific features of natural killer cells. Nat Rev Immunol 11: 658-671.
36. t Hart BA, Gran B, Weissert R, (2011) EAE: imperfect but useful models of multiple sclerosis. Trends Mol Med 17: 119-125.
37. Taniguchi T, Minami Y, (1993) The IL-2/IL-2 receptor system: a current overview. Cell 73: 5-8.
38. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY, (2005) A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6: 1142-1151.
39. Meazza R, Azzarone B, Orengo AM, Ferrini S, (2011) Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol 2011: 861920.
40. Mi S, Hu B, Hahm K, Luo Y, Kam Hui ES, et al. (2007) LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 13: 1228-1233.